Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells

Annals of Surgical Oncology

Volumn 4, Issue 2, 1997, Pages 141-148

  Buell, Joseph F ^a   Reed, Eddie ^a   Lee, Kang Bo ^a   Parker, Ricardo J ^a   Venzon, David J ^a   Amikura, Katsumi ^a   Scott Arnold, W ^a   Fraker, Douglas L ^a   Alexander, H Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cisplatin; Gastric adenocarcinoma; Hyperthermia; TNF

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CELL CULTURE; DRUG POTENTIATION; HUMAN; HYPERTHERMIC THERAPY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; STOMACH TUMOR;

ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; DRUG SYNERGISM; HUMANS; HYPERTHERMIA, INDUCED; SPECTROPHOTOMETRY, ATOMIC; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031087397     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02303797     Document Type: Article

References (29)

1. Fujimoto S, Shgrestha RD, Kokubun M, et al. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg 1988;208:36-41.
2. Fujimoto S, Shrestha RD, Kokuban M, et al. Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer. Ann Surg 1990;212:592-6.
3. Fujimoto S, Shrestha RD, Kokubun M, et al. Clinical trial with surgery and intraperitoneal hyperthermic perfusion for peritoneal recurrence of gastrointestinal cancer. Cancer 1989;64:154-60.
4. Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 1988;61:232-7.
5. Alexander HR, Buell JF, Fraker DL. Rationale and clinical status of continuous hyperthermic peritoneal perfusion for the treatment of peritoneal carcinomatosis. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Principles and practice of oncology: PPO updates. Philadelphia: JB Lippincott, 1995:1-9.
6. Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and Mitomycin C. Cancer Res 1980;40:1165-8.
7. Yamaguchi A, Tsukioka Y, Fushida S, et al. Intraperitoneal hyperthermic treatment for peritoneal dissemination of colorectal cancers. Dis Colon Rectum 1992;35:964-8.
8. Fujimura T, Yonemura Y, Muraoka K, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg 1994;18:150-5.
9. Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Cancer 1994;73:2048-52.
10. Fujimura T, Yonemura Y, Fushida S, et al. Continuous hyperthermic peritoneal perfusion for the treatment of perito-neal dissemination in gastric cancers and subsequent second-look operation. Cancer 1990;65:65-71.
11. Leinard D, Lejeune F, Delmotte J, et al. High doses of rTNFα in combination with IFN-gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
12. Fraker DL, Alexander HR. Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: JB Lippincott, 1994:179-92.
13. Fraker DL, Alexander HR. The use of tumor necrosis factor in isolated limb perfusions for melanoma and sarcoma. In: DeVita V, Hellman S, Rosenberg SA, eds. Principles and practice of oncology. Philadelphia: JB Lippincott, 1993.
14. Rath U, Kaufmann M, Schmid H, et al. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. Eur J Cancer 1991;27:121-5.
15. Hardy J, Jones A, Gore ME, Viner C, Selby P, Wiltshaw E. Treatment of advanced ovarian cancer with intraperitoneal tumour necrosis factor. Eur J Cancer 1990;26:771.
16. Fraker DL, Alexander HR, Pass HI. Biologic therapy with TNF: systemic administration and isolation-perfusion. In: De Vita V, Hellman S, Rosenberg SA, eds. Biologic therapy of cancer. Philadelphia: JB Lippincott, 1995:329-45.
17. Markman M, Reichman B, Ianotti N, et al. Phase I trial of recombinant tumor necrosis factor administered by the intraperitoneal route. Reg Cancer Treat 1989;2:174-7.
18. Raeth U, Schmid H, Karck U, Kempeni J, Schlick E, Kaufmann M. Phase II trial of recombinant human tumor necrosis factorα (rHuTNF) in patients with malignant ascites from ovarian carcinomas and non-ovarian tumors with intraperitoneal spread. Proc ASCO 1991;10:187.
19. Yamauchi N, Watanabe N, Maeda M, et al. Mechanism of synergistic cytotoxic effect between tumor necrosis factor and hyperthermia. Jpn J Cancer Res 1992;83:540-5.
20. Klostergaard J, Leroux E, Siddik ZH, Khodadadian M, Tomasovic SP. Enhanced sensitivity of human colon tumor cell lines in vitro in response to thermochemoimmunotherapy. Cancer Res 1992;52:5271-7.
21. Flessner MF, Dedrick RL. Intraperitoneal chemotherapy. In: Gokal R, Nolph KD, eds. The textbook of peritoneal dialysis. The Netherlands: Kluwer Academic, 1994:769-89.
22. Markman M. Intraperitoneal chemotherapy for malignant diseases of the gastrointestinal tract. Surg Gynecol Obstet 1987;164:89-93.
23. Barloie B, Corry PM, Drewinko B. In vitro thermotherapy of colon cancer cells with cis-dischlorodiammineplatinum(II) and mitomycin C. Client Biol Interact 1987;61:1.
24. Herman TS, Teicher BA, Cathcart KNS, Kaufman ME, Lee JB, Lee MN. Effect of hyperthermia on cis-diamminedichlorplatinum(II), (rhodamine123)2[tetrachloroplatinum(II)], in a human squamous cell carcinoma line and cis-diamminedichloroplatinum(II)-resistant subline. Cancer Res 1988;48:5101.
25. Overgaard J, Radacic MM, Gran C. Interaction of hyperthermia and cis-diamminedichloroplatinum(II) alone or combined with radiation in a C3H mammary carcinoma in vivo. Cancer Res 1991;51:707.
26. Alberts DS, Peng YM, Chen G, Moon TE, Cetas TC, Hoeschele JD. Therapeutic synergism of hyperthermia-cis-platinum in a mouse model. J Natl Cancer Inst 1980;65:455.
27. Wondergem J, Bulger RE, Strebel FR, et al. Effect of cis-diamminedichloroplatinum(II) combined with whole body hyperthermia on renal injury. Cancer Res 1988;48:440-6.
28. Ohno S, Siddik ZH, Kido Y, Zwelling LA, Bull JM. Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cis-platin-induced cytotoxicity in L1210 cells. Cancer Chemother Pharmacol 1994;34:302-6.
29. Reed E, Parker RJ, Gill I, et al. Platinum-DNA adduct in leukocyte DNA of a chohort of 49 patients with 24 different types of malignancies. Cancer Res 1993;53:3694-9.